Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
复制标题
比较晚期卵巢癌的两种联合化疗方案 (CHAP-5 v CP) 的随机试验。
DOI：
--
复制
发表时间：
1987
影响因子：
45.3
通讯作者：
J. Vermorken
中科院分区：
文献类型：
--
作者：
J. Neijt;W. W. ten Bokkel Huinink;M. van der Burg;A. V. van Oosterom;P. Willemse;A. Heintz;M. van Lent;J. Trimbos;J. Bouma;J. Vermorken
One hundred ninety-one patients with advanced epithelial ovarian carcinoma were treated with either a combination of doxorubicin and a five-day course of cisplatin alternating with cyclophosphamide and hexamethylmelamine orally for 14 days (CHAP-5) or cyclophosphamide and cisplatin both administered intravenously (IV) on a single day at 3-week intervals (CP). At a median follow-up time of 45 months, treatment with each of these combinations resulted in the same remission rates (80% and 74%, respectively) and exactly the same progression-free survival and overall survival (median, 26 months). Despite adequate hydration, more renal toxicity was encountered in the CP-treated patients than in those who received CHAP-5. Disabling neurotoxicity and severe myelosuppression were encountered more frequently in the patients treated with CHAP-5. Because the toxicity was lower and CP treatment required shorter hospitalization, the single-day regimen was considered preferable for future use. The Karnofsky index was the only independent predictor for response, whereas both this index and the size of residual tumor before chemotherapy were predictive of survival. After correcting for other prognostic factors, it was determined that tumor size associated with improved survival was less than 1 cm. The site of metastases in International Federation of Gynecology and Obstetrics (FIGO) stage IV patients did not influence survival within this category. The results of this study confirm our previous findings that patients with microscopic remnants at second-look have a survival similar to that of patients who are histopathologically free of disease. This makes the significance of so-called pathologically confirmed complete remission questionable. The survival benefit of debulking surgery performed during chemotherapy seems only minimal for patients in whom debulking has already been attempted before treatment. Like others, we have found the CP regimen to have a good therapeutic index.
卵巢癌的当前治疗：概述。
影响因子：
4
作者：
Thigpen,T;Blessing,JA
通讯作者：
Blessing,JA
影响因子：
45.3
作者：
ANDERSON, JR;CAIN, KC;GELBER, RD
通讯作者：
GELBER, RD